Literature DB >> 21680298

Current opinion in cervix carcinoma.

Silvia Rodríguez Villalba1, Carmen Díaz-Caneja Planell, José Manuel Cervera Grau.   

Abstract

We review the current status of the conventional therapeutical approaches of cervix carcinoma. Radical hysterectomy remains as the main stone in early stages and play an important role in relapses. Radiotherapy plays an important role in early and advance disease. New techniques and image expand indications and treatment possibilities. Chemotherapy platinum based with radiation therapy goes on being the standard treatment in advanced tumours or non surgical candidates. New systemic strategies are being explored in clinical trials.

Entities:  

Mesh：

Year:  2011        PMID： 21680298     DOI： 10.1007/s12094-011-0671-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  37 in total

1.  Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer.

Authors:  Chien-Chih Chen; Jin-Ching Lin; Jian-Sheng Jan; Shih-Chu Ho; Lily Wang
Journal:  Gynecol Oncol       Date:  2011-04-22       Impact factor: 5.482

2.  Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.

Authors:  R Pearcey; M Brundage; P Drouin; J Jeffrey; D Johnston; H Lukka; G MacLean; L Souhami; G Stuart; D Tu
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.

Authors:  Mariana Guerrero; X Allen Li; Lijun Ma; Jeanette Linder; Chad Deyoung; Beth Erickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

Review 4.  Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology.

Authors:  Daniel S Higginson; David E Morris; Ellen L Jones; Daniel Clarke-Pearson; Mahesh A Varia
Journal:  Gynecol Oncol       Date:  2010-12-30       Impact factor: 5.482

5.  A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix.

Authors:  J Herod; A Burton; J Buxton; J Tobias; D Luesley; S Jordan; J Dunn; C J Poole
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

6.  Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies.

Authors:  J C Roeske; A Lujan; J Rotmensch; S E Waggoner; D Yamada; A J Mundt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

7.  A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients.

Authors:  Bulent Aydogan; Arno J Mundt; Brett D Smith; Loren K Mell; Steve Wang; Harold Sutton; John C Roeske
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-01       Impact factor: 7.038

8.  Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.

Authors:  Huijun Chen; Chuan Liang; Lei Zhang; Shuang Huang; Xufeng Wu
Journal:  Gynecol Oncol       Date:  2008-07-07       Impact factor: 5.482

9.  Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association.

Authors:  M H Tattersall; V Lorvidhaya; V Vootiprux; A Cheirsilpa; F Wong; T Azhar; H P Lee; S B Kang; A Manalo; M S Yen
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  Dosimetric comparison of intensity-modulated, conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a retrospective planning study.

Authors:  Philip Chan; Inhwan Yeo; Gregory Perkins; Anthony Fyles; Michael Milosevic
Journal:  Radiat Oncol       Date:  2006-05-04       Impact factor: 3.481
View more
  5 in total

1.  Cytotoxic and apoptotic activities of black widow spiderling extract against HeLa cells.

Authors:  Xiaozhen Peng; Zhipan Dai; Qian Lei; Long Liang; Shuai Yan; Xianchun Wang
Journal:  Exp Ther Med       Date:  2017-04-27       Impact factor: 2.447

2.  MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.

Authors:  Marco Perez; Juan M Praena-Fernandez; Blanca Felipe-Abrio; Maria A Lopez-Garcia; Antonio Lucena-Cacace; Angel Garcia; Matilde Lleonart; Guiovanna Roncador; Juan J Marin; Amancio Carnero
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

3.  Anti-EGFR-Conjugated Hollow Gold Nanospheres Enhance Radiocytotoxic Targeting of Cervical Cancer at Megavoltage Radiation Energies.

Authors:  Jiao Liu; Ying Liang; Ting Liu; Dengke Li; Xingsheng Yang
Journal:  Nanoscale Res Lett       Date:  2015-05-15       Impact factor: 4.703

4.  Angelicin inhibits the malignant behaviours of human cervical cancer potentially via inhibiting autophagy.

Authors:  Yiran Wang; Yueqi Chen; Xuedan Chen; Yan Liang; Dapeng Yang; Jiao Dong; Neng Yang; Zhiqing Liang
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

5.  Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.

Authors:  Ting Liu; Yueyang Liu; Xiangxiang Bao; Jiguang Tian; Yang Liu; Xingsheng Yang
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.